ACS Chemical Biology

March 28, 2019

Cancer’s SOS

Stephen Fesik and colleagues are advancing cancer drug discovery with the characterization of small molecules that modulate RAS, an important target for anti-cancer therapies.

By Sanjay Mishra
January 19, 2017

COX-2 ‘conjugate’ may slow growth of some tumors: study

More than a decade after the anti-inflammatory drugs Vioxx and Bextra were pulled from the market because of a heightened risk of heart attack and stroke in some patients, COX-2 inhibitors may be on the verge of a comeback, this time as anti-cancer agents.

By Bill Snyder
September 12, 2014

Schizophrenia ‘switches’ discovered

Drugs developed at Vanderbilt could provide a new way to treat schizophrenia in a personalized way.

By Bill Snyder